ArticleJournal of cancer & allied specialties2026
Outcomes of Pediatric and Adolescent Girls with Malignant Ovarian Germ Cell Tumors after Chemotherapy and Surgery: A Single Institutional Experience.
Article in Journal of cancer & allied specialties, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malignant ovarian germ cell tumors are rare and vital cancers in the pediatric age group of females, affecting 1-2% of all ovarian malignancies. Advances in surgical management, chemotherapy, and patient care have significantly improved survival. Materials and Methods: This retrospective study investigates the treatment outcomes of 116 pediatric patients diagnosed with Malignant ovarian germ cell tumors at a tertiary care center in Pakistan between 1999 and 2022. The study focuses on patterns of care, survival rates, recurrence, and complications associated with therapy. Results: The median age was 13.5 years, with dysgerminomas predominating (38.7%). Most patients had upfront surgery (87.9%), followed by adjuvant chemotherapy, including JEB (Carboplatin, etoposide, bleomycin) (64.7%), BEP (bleomycin, etoposide, cisplatin) (25.0%), and PEB (cisplatin, Etoposide, Bleomycin) (4.3%). The five-year event-free survival (EFS) and overall survival (OS) were 87.1% and 90.5%, respectively. Histology, chemotherapy regimen, and risk group classification were key factors influencing survival, with dysgerminoma showing the best prognosis. In patients whose tumor markers normalized rapidly, event-free survival (EFS) was better. Relapsed disease was observed in 2.6% of patients, and disease progression occurred in 7.8%. Conclusion: Our study shows good outcomes for girls with ovarian tumors. This study highlights the effectiveness of multimodal treatment strategies, including both surgery and chemotherapy, in improving survival outcomes for pediatric patients with malignant ovarian germ cell tumors in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.